Medpace (NASDAQ:MEDP) VP Susan Burwig Sells 20,000 Shares of Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) VP Susan Burwig sold 20,000 shares of Medpace stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $609.15, for a total value of $12,183,000.00. Following the completion of the transaction, the vice president directly owned 27,500 shares of the company’s stock, valued at $16,751,625. This represents a 42.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Medpace Stock Down 0.9%

Shares of MEDP stock opened at $606.60 on Thursday. The firm has a market cap of $17.09 billion, a price-to-earnings ratio of 42.42, a PEG ratio of 2.67 and a beta of 1.42. The stock has a 50-day moving average price of $556.49 and a 200 day moving average price of $440.30. Medpace Holdings, Inc. has a 12 month low of $250.05 and a 12 month high of $626.26.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, topping the consensus estimate of $3.50 by $0.36. The business had revenue of $659.90 million for the quarter, compared to analyst estimates of $640.49 million. Medpace had a net margin of 18.36% and a return on equity of 91.88%. Medpace’s quarterly revenue was up 23.7% compared to the same quarter last year. During the same quarter last year, the firm earned $3.01 EPS. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. Sell-side analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on MEDP. Barclays boosted their price objective on shares of Medpace from $425.00 to $485.00 and gave the stock an “underweight” rating in a research note on Friday, October 24th. Mizuho boosted their price objective on shares of Medpace from $575.00 to $655.00 and gave the company an “outperform” rating in a report on Friday, October 24th. Cowen restated a “sell” rating on shares of Medpace in a research report on Friday, October 24th. Wall Street Zen upgraded shares of Medpace from a “hold” rating to a “buy” rating in a research report on Saturday, October 25th. Finally, Zacks Research raised shares of Medpace from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 27th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, ten have given a Hold rating and four have given a Sell rating to the company. According to data from MarketBeat, Medpace presently has a consensus rating of “Hold” and an average target price of $487.18.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Private Advisor Group LLC boosted its holdings in Medpace by 12.3% in the 1st quarter. Private Advisor Group LLC now owns 2,502 shares of the company’s stock worth $762,000 after buying an additional 275 shares during the period. Assetmark Inc. lifted its position in Medpace by 24.9% during the first quarter. Assetmark Inc. now owns 216 shares of the company’s stock valued at $66,000 after purchasing an additional 43 shares during the last quarter. HB Wealth Management LLC purchased a new position in Medpace in the first quarter worth $256,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Medpace by 4.9% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,046 shares of the company’s stock valued at $2,147,000 after purchasing an additional 326 shares during the last quarter. Finally, LPL Financial LLC raised its stake in shares of Medpace by 2.3% during the first quarter. LPL Financial LLC now owns 18,374 shares of the company’s stock worth $5,469,000 after acquiring an additional 414 shares in the last quarter. 77.98% of the stock is owned by institutional investors.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.